163 related articles for article (PubMed ID: 37719112)
1. Effect of apatinib on the pharmacokinetics of tramadol and O-desmethyltramadol in rats.
Bao SS; Tang PF; Gao NY; Xiao ZX; Qian JC; Zheng L; Hu GX; Xu HH
PeerJ; 2023; 11():e16051. PubMed ID: 37719112
[TBL] [Abstract][Full Text] [Related]
2. The effect of icotinib or apatinib on the pharmacokinetic profile of oxycodone in rats and the underlying mechanism.
Zhou Q; Ye F; Ye Z; Gao N; Kong Q; Hu X; Qian J; Wu B
PeerJ; 2023; 11():e16601. PubMed ID: 38089912
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Effects of Apatinib on the Pharmacokinetics of Venlafaxine and O-desmethylvenlafaxine in SD Male Rats by UPLC-MS/MS.
Bao SS; Wen J; Lin QM; Li YH; Huang YG; Zhou HY; Hu GX
Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):721-726. PubMed ID: 29964362
[TBL] [Abstract][Full Text] [Related]
4. The effect of apatinib on pharmacokinetic profile of buspirone both in vivo and in vitro.
Zhang XD; Li YH; Chen DX; You WW; Hu XX; Chen BB; Hu GX; Qian JC
J Pharm Pharmacol; 2020 Oct; 72(10):1405-1411. PubMed ID: 32608074
[TBL] [Abstract][Full Text] [Related]
5. Effects of Avitinib on CYP450 Enzyme Activity in vitro and in vivo in Rats.
Shi Y; Meng D; Wang S; Geng P; Xu T; Zhou Q; Zhou Y; Li W; Chen X
Drug Des Devel Ther; 2021; 15():3661-3673. PubMed ID: 34456561
[TBL] [Abstract][Full Text] [Related]
6. Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6-Mediated Drug-Drug Interactions on Tramadol and O-Desmethyltramadol Exposures via Allosteric and Competitive Inhibition.
Long T; Cristofoletti R; Cicali B; Michaud V; Dow P; Turgeon J; Schmidt S
J Clin Pharmacol; 2022 Jan; 62(1):76-86. PubMed ID: 34383318
[TBL] [Abstract][Full Text] [Related]
7. Effects of the central analgesic tramadol and its main metabolite, O-desmethyltramadol, on rat locus coeruleus neurones.
Sevcik J; Nieber K; Driessen B; Illes P
Br J Pharmacol; 1993 Sep; 110(1):169-76. PubMed ID: 8220877
[TBL] [Abstract][Full Text] [Related]
8. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes.
Stamer UM; Musshoff F; Kobilay M; Madea B; Hoeft A; Stuber F
Clin Pharmacol Ther; 2007 Jul; 82(1):41-7. PubMed ID: 17361124
[TBL] [Abstract][Full Text] [Related]
9. Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of
Haage P; Kronstrand R; Josefsson M; Calistri S; van Schaik RHN; Green H; Kugelberg FC
Pharmacol Res Perspect; 2018 Jul; 6(4):e00419. PubMed ID: 29992026
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous analysis of tramadol, O-desmethyltramadol, and N-desmethyltramadol enantiomers in rat plasma by high-performance liquid chromatography-tandem mass spectrometry: application to pharmacokinetics.
Godoy AL; De Moraes NV; Martinez EZ; Carvalho TM; Marques MP; Lanchote VL
Chirality; 2011 Apr; 23(4):287-93. PubMed ID: 21384434
[TBL] [Abstract][Full Text] [Related]
11. Influence of Obesity and Type 2 Diabetes Mellitus on the Pharmacokinetics of Tramadol After Single Oral Dose Administration.
Porażka J; Szałek E; Połom W; Czajkowski M; Grabowski T; Matuszewski M; Grześkowiak E
Eur J Drug Metab Pharmacokinet; 2019 Aug; 44(4):579-584. PubMed ID: 30778911
[TBL] [Abstract][Full Text] [Related]
12. The effect of shikonin on the metabolism of lapatinib in vitro, and in vivo.
Hu Y; Xie S; Xia H; Chen J; Yang Y; Zhan R
Toxicol Appl Pharmacol; 2024 Jan; 482():116797. PubMed ID: 38160892
[TBL] [Abstract][Full Text] [Related]
13. Effect of the cytochrome P450 2D6*10 genotype on the pharmacokinetics of tramadol in post-operative patients.
Xu J; Zhang XC; Lv XQ; Xu YY; Wang GX; Jiang B; Cai L; Cai XJ
Pharmazie; 2014 Feb; 69(2):138-41. PubMed ID: 24640604
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effects of main active metabolites of tramadol, (+)-O-desmethyltramadol and (-)-O-desmethyltramadol, in rats.
Valle M; Garrido MJ; Pavón JM; Calvo R; Trocóniz IF
J Pharmacol Exp Ther; 2000 May; 293(2):646-53. PubMed ID: 10773040
[TBL] [Abstract][Full Text] [Related]
15. Enantiomeric determination of tramadol and O-desmethyltramadol in human plasma by fast liquid chromatographic technique coupled with mass spectrometric detection.
Chytil L; Matousková O; Cerná O; Pokorná P; Vobruba V; Perlík F; Slanar O
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Feb; 878(3-4):481-6. PubMed ID: 20018572
[TBL] [Abstract][Full Text] [Related]
16. CYP2D6 gene polymorphism and apatinib affect the metabolic profile of fluvoxamine.
Ye Z; Chen B; Gao N; Kong Q; Hu X; Lu Z; Qian J; Hu G; Cai J; Wu B
Front Pharmacol; 2022; 13():985159. PubMed ID: 36120346
[TBL] [Abstract][Full Text] [Related]
17. An investigation into possible interactions among four vascular epidermal growth factor receptor-tyrosine kinase inhibitors with gefitinib.
Wang C; Ying L; Jin M; Zhang F; Shi D; Dai Y; Zhou Z
Cancer Chemother Pharmacol; 2021 Jan; 87(1):43-52. PubMed ID: 33170322
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of fluoxetine and duloxetine on the pharmacokinetics of metoprolol in vivo and in vitro.
Xu T; Gao N; Li Y; Wang R; Chen B; Hu G; Zhang X
Fundam Clin Pharmacol; 2022 Dec; 36(6):1057-1065. PubMed ID: 35510497
[TBL] [Abstract][Full Text] [Related]
19. The pharmacokinetics, metabolism and urinary detection time of tramadol in camels.
Elghazali M; Barezaik IM; Abdel Hadi AA; Eltayeb FM; Al Masri J; Wasfi IA
Vet J; 2008 Nov; 178(2):272-7. PubMed ID: 17904881
[TBL] [Abstract][Full Text] [Related]
20. Glucuronidation of racemic O-desmethyltramadol, the active metabolite of tramadol.
Lehtonen P; Sten T; Aitio O; Kurkela M; Vuorensola K; Finel M; Kostiainen R
Eur J Pharm Sci; 2010 Nov; 41(3-4):523-30. PubMed ID: 20797434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
